Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*

被引：9

作者：

Wilson, Wyndham H. ^{[1
]}

Phillips, Tycel ^{[2
]}

Popplewell, Leslie ^{[3
]}

de Vos, Sven ^{[4
]}

Chhabra, Saurabh ^{[5
]}

Kimball, Amy S. ^{[6
]}

Beaupre, Darrin ^{[7
]}

Huang, Da Wei ^{[1
]}

Wright, George ^{[1
]}

Kwei, Kevin ^{[8
]}

Ping, Jerry ^{[9
]}

Neuenburg, Jutta K. ^{[10
]}

Staudt, Louis M. ^{[11
]}

机构：

[1] NCI, Lymphoma Therapeut Sect, 9609 Med Ctr Dr, Bethesda, MD 20892 USA

[2] Univ Michigan, Div Hematol & Oncol, Ann Arbor, MI 48109 USA

[3] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplant, 1500 E Duarte Rd, Duarte, CA 91010 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[5] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

[6] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[7] Pharmacyclics LLC, Early Dev & Immunotherapy, Sunnyvale, CA USA

[8] Pharmacyclics LLC, Dept Translat Med, Sunnyvale, CA USA

[9] Pharmacyclics LLC, Dept Stat, Sunnyvale, CA USA

[10] Pharmacyclics LLC, Dept Oncol, Sunnyvale, CA USA

[11] NCI, Lymphoid Malignancies Branch, Bethesda, MD 20892 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 09期

关键词：

Ibrutinib; lenalidomide; dose-adjusted EPOCH-R; diffuse large B-cell lymphoma; activated B-cell-like; germinal center B-cell-like; GERMINAL CENTER; RITUXIMAB; CHEMOTHERAPY; TRIAL; COMBINATION; THERAPY; CHOP;

D O I：

10.1080/10428194.2021.1907371

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in ABC DLBCL and may augment salvage chemotherapy. In part 1 of this phase 1b/2 study (NCT02142049), patients with relapsed/refractory DLBCL received ibrutinib 560 mg and escalating doses of lenalidomide on Days 1-7 with DA-EPOCH-R (Days 1-5) in 21-day cycles. In part 1 (N = 15), the maximum tolerated dose was not reached with lenalidomide 25 mg (recommended part 2 dose [RP2D]); most common grade >= 3 adverse events were anemia (73%) and febrile neutropenia (47%); the overall response rate (ORR) was 40%. At the RP2D (n = 26), ORR was 71% in non-GCB and 64% in ABC. Ibrutinib and lenalidomide with DA-EPOCH-R had a manageable safety profile and antitumor activity in relapsed/refractory DLBCL, especially the non-GCB subtype.

引用

页码：2094 / 2106

页数：13

共 39 条

[1]

[Anonymous], 2020, IMBRUVICA IBRUTINIB

[2]

[Anonymous], 2014, IMBRUVICA 140 MG HAR

[3] Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma [J].

Bao, Fang ;

Wan, Wei ;

He, Ting ;

Qi, Feifei ;

Liu, Guanghua ;

Hu, Kai ;

Lu, Xin-an ;

Yang, Ping ;

Dong, Fei ;

Wang, Jing ;

Jing, Hongmei .

CANCER GENE THERAPY, 2019, 26 (7-8) :248-255

[4] Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie ;

Sharman, Jeff P. ;

Wierda, William ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Luan, Ying ;

Liu, Emily A. ;

Dean, James P. ;

O'Brien, Susan .

CLINICAL CANCER RESEARCH, 2020, 26 (15) :3918-3927

[5]

Carlo-Stella C., 2020, BLOOD

[6] The international harmonization project for response criteria in lymphoma clinical trials [J].

Cheson, Bruce D. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (05) :841-+

[7] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[8] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[9] Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma [J].

Davis, R. Eric ;

Ngo, Vu N. ;

Lenz, Georg ;

Tolar, Pavel ;

Young, Ryan M. ;

Romesser, Paul B. ;

Kohlhammer, Holger ;

Lamy, Laurence ;

Zhao, Hong ;

Yang, Yandan ;

Xu, Weihong ;

Shaffer, Arthur L. ;

Wright, George ;

Xiao, Wenming ;

Powell, John ;

Jiang, Jian-Kang ;

Thomas, Craig J. ;

Rosenwald, Andreas ;

Ott, German ;

Muller-Hermelink, Hans Konrad ;

Gascoyne, Randy D. ;

Connors, Joseph M. ;

Johnson, Nathalie A. ;

Rimsza, Lisa M. ;

Campo, Elias ;

Jaffe, Elaine S. ;

Wilson, Wyndham H. ;

Delabie, Jan ;

Smeland, Erlend B. ;

Fisher, Richard I. ;

Braziel, Rita M. ;

Tubbs, Raymond R. ;

Cook, J. R. ;

Weisenburger, Dennis D. ;

Chan, Wing C. ;

Pierce, Susan K. ;

Staudt, Louis M. .

NATURE, 2010, 463 (7277) :88-U97

[10] Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells [J].

Davis, RE ;

Brown, KD ;

Siebenlist, U ;

Staudt, LM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1861-1874

← 1 2 3 4 →